Navigation Links
Shengtai Pharmaceutical Schedules 2009 Second Quarter Financial Results and Conference Call

WEIFANG, Shandong, China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it will issue financial results for the three months ended December 31, 2008 before the stock market opens on Friday, February 13, 2009. Management will conduct a conference call on Friday, February 13, 2009 at 9:00 A.M. Eastern Standard Time to discuss these results. A question and answer session will follow management's presentation.

Mr. Qingtai Liu (Chief Executive Officer), Ms. Yiru Melody Shi (Chief Financial Officer), and Ms. Haining Michelle Wang (Investor Relations Manager) will be the primary speakers on the call.

A live webcast of the conference call will be available by accessing the below website at or on the Investor Relations page of Shengtai Pharmaceutical's web site at . Please visit the Web site at least 15 minutes early to register for the webcast and download any necessary audio software.

To participate, please call the following numbers ten minutes before the call start time:

Phone Number + 1 (877) 407-8035 (North America)

Phone Number + 1 (201) 689-8035 (International)

A replay of the call will be available through Saturday, February 21, 2009, at 11:59 P.M. Eastern Standard Time. For the replay, please call:

     Phone Number +1 (877) 660-6853 (North America)
     Phone Number +1 (201) 612-7415 (International)
     Account Number: 286
     Conference ID Number: 313673

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc., through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China. For more information about Shengtai Pharmaceutical, Inc., please visit .

Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release and oral statements made by the Company constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, the Company's planned capacity expansion and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large-scale implementation of the Company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

    For more information, please contact:

    Shengtai Pharmaceutical, Inc.
     Ms. Yiru Melody Shi
     Chief Financial Officer

     Eddie Cheung
     Investor Relations
     Tel:   +1-646-284-9414

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Shengtai Pharmaceutical, Inc. Reports Record 2007 Annual Results
2. Shengtai Pharmaceutical, Inc. Reports First Quarter Results of Fiscal Year 2008
3. Shengtai Pharmaceutical, Inc. to Present at Roth Capital Phoenix Conference
4. Shengtai Pharmaceutical, Inc. to Present at Roth Conference
5. Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008
6. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
7. Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008
8. Shengtai Pharmaceutical Expands International Sales Program
9. Shengtai Pharmaceutical to Present at Roth 21st Annual OC Growth Stock Conference
10. Shengtai Pharmaceutical, Inc. Comments on Chinas Recently Approved Health Care Reform Plan
11. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
Post Your Comments:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
Breaking Medicine Technology: